- Home
- CRVS vs FLC Comparison
CRVS vs FLC Comparison
Compare CRVS & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- FLC
- Stock Information
- Founded
- CRVS 2014
- FLC 2003
- Country
- CRVS United States
- FLC United States
- Employees
- CRVS N/A
- FLC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CRVS Health Care
- FLC Finance
- Exchange
- CRVS Nasdaq
- FLC Nasdaq
- Market Cap
- CRVS 206.5M
- FLC 171.6M
- IPO Year
- CRVS 2016
- FLC N/A
- Fundamental
- Price
- CRVS $3.61
- FLC $16.80
- Analyst Decision
- CRVS Strong Buy
- FLC
- Analyst Count
- CRVS 3
- FLC 0
- Target Price
- CRVS $16.33
- FLC N/A
- AVG Volume (30 Days)
- CRVS 1.6M
- FLC 37.8K
- Earning Date
- CRVS 05-08-2025
- FLC 01-01-0001
- Dividend Yield
- CRVS N/A
- FLC 6.64%
- EPS Growth
- CRVS N/A
- FLC N/A
- EPS
- CRVS N/A
- FLC N/A
- Revenue
- CRVS N/A
- FLC N/A
- Revenue This Year
- CRVS N/A
- FLC N/A
- Revenue Next Year
- CRVS N/A
- FLC N/A
- P/E Ratio
- CRVS N/A
- FLC N/A
- Revenue Growth
- CRVS N/A
- FLC N/A
- 52 Week Low
- CRVS $1.75
- FLC $12.62
- 52 Week High
- CRVS $10.00
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CRVS 50.22
- FLC 63.69
- Support Level
- CRVS $3.46
- FLC $15.92
- Resistance Level
- CRVS $4.53
- FLC $16.78
- Average True Range (ATR)
- CRVS 0.28
- FLC 0.20
- MACD
- CRVS 0.02
- FLC 0.07
- Stochastic Oscillator
- CRVS 32.60
- FLC 96.92
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.